The mTOR pathway in hepatic malignancies

Mamatha Bhat, Nahum Sonenberg, Gregory James Gores

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

The mechanistic/mammalian target of rapamycin (mTOR) pathway plays a critical role in cellular metabolism, growth, and proliferation and has been evaluated as a target for therapy in various malignancies. The mTOR pathway is a major tumor-initiating pathway in hepatocellular carcinoma, with up-regulation seen in up to 50% of tumors. Metformin, which represses mTOR signaling by activating adenosine monophosphate-activated protein kinase, has been shown to decrease liver carcinogenesis in population studies. mTOR inhibitors such as everolimus have been evaluated as adjunctive chemotherapy with some success, although efficacy has been limited by the lack of complete mTOR pathway inhibition. The active site mTOR inhibitors hold greater promise, given that they offer complete mTOR suppression. There is also evidence of mTOR pathway activation in cholangiocarcinoma, although its biological significance in initiating and promoting tumor progression remains ambiguous. This review provides an overview of the complex biochemistry behind the mTOR pathway and its role in carcinogenesis, especially as it pertains to hepatic malignancies.

Original languageEnglish (US)
Pages (from-to)810-818
Number of pages9
JournalHepatology
Volume58
Issue number2
DOIs
StatePublished - Aug 2013

Fingerprint

Sirolimus
Liver
Neoplasms
Carcinogenesis
Cholangiocarcinoma
Metformin
Adenosine Monophosphate
Biochemistry
Protein Kinases
Hepatocellular Carcinoma
Catalytic Domain
Up-Regulation
Drug Therapy
Growth

ASJC Scopus subject areas

  • Hepatology

Cite this

The mTOR pathway in hepatic malignancies. / Bhat, Mamatha; Sonenberg, Nahum; Gores, Gregory James.

In: Hepatology, Vol. 58, No. 2, 08.2013, p. 810-818.

Research output: Contribution to journalArticle

Bhat, Mamatha ; Sonenberg, Nahum ; Gores, Gregory James. / The mTOR pathway in hepatic malignancies. In: Hepatology. 2013 ; Vol. 58, No. 2. pp. 810-818.
@article{91bbcdd96f184b7690a4321739164916,
title = "The mTOR pathway in hepatic malignancies",
abstract = "The mechanistic/mammalian target of rapamycin (mTOR) pathway plays a critical role in cellular metabolism, growth, and proliferation and has been evaluated as a target for therapy in various malignancies. The mTOR pathway is a major tumor-initiating pathway in hepatocellular carcinoma, with up-regulation seen in up to 50{\%} of tumors. Metformin, which represses mTOR signaling by activating adenosine monophosphate-activated protein kinase, has been shown to decrease liver carcinogenesis in population studies. mTOR inhibitors such as everolimus have been evaluated as adjunctive chemotherapy with some success, although efficacy has been limited by the lack of complete mTOR pathway inhibition. The active site mTOR inhibitors hold greater promise, given that they offer complete mTOR suppression. There is also evidence of mTOR pathway activation in cholangiocarcinoma, although its biological significance in initiating and promoting tumor progression remains ambiguous. This review provides an overview of the complex biochemistry behind the mTOR pathway and its role in carcinogenesis, especially as it pertains to hepatic malignancies.",
author = "Mamatha Bhat and Nahum Sonenberg and Gores, {Gregory James}",
year = "2013",
month = "8",
doi = "10.1002/hep.26323",
language = "English (US)",
volume = "58",
pages = "810--818",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - The mTOR pathway in hepatic malignancies

AU - Bhat, Mamatha

AU - Sonenberg, Nahum

AU - Gores, Gregory James

PY - 2013/8

Y1 - 2013/8

N2 - The mechanistic/mammalian target of rapamycin (mTOR) pathway plays a critical role in cellular metabolism, growth, and proliferation and has been evaluated as a target for therapy in various malignancies. The mTOR pathway is a major tumor-initiating pathway in hepatocellular carcinoma, with up-regulation seen in up to 50% of tumors. Metformin, which represses mTOR signaling by activating adenosine monophosphate-activated protein kinase, has been shown to decrease liver carcinogenesis in population studies. mTOR inhibitors such as everolimus have been evaluated as adjunctive chemotherapy with some success, although efficacy has been limited by the lack of complete mTOR pathway inhibition. The active site mTOR inhibitors hold greater promise, given that they offer complete mTOR suppression. There is also evidence of mTOR pathway activation in cholangiocarcinoma, although its biological significance in initiating and promoting tumor progression remains ambiguous. This review provides an overview of the complex biochemistry behind the mTOR pathway and its role in carcinogenesis, especially as it pertains to hepatic malignancies.

AB - The mechanistic/mammalian target of rapamycin (mTOR) pathway plays a critical role in cellular metabolism, growth, and proliferation and has been evaluated as a target for therapy in various malignancies. The mTOR pathway is a major tumor-initiating pathway in hepatocellular carcinoma, with up-regulation seen in up to 50% of tumors. Metformin, which represses mTOR signaling by activating adenosine monophosphate-activated protein kinase, has been shown to decrease liver carcinogenesis in population studies. mTOR inhibitors such as everolimus have been evaluated as adjunctive chemotherapy with some success, although efficacy has been limited by the lack of complete mTOR pathway inhibition. The active site mTOR inhibitors hold greater promise, given that they offer complete mTOR suppression. There is also evidence of mTOR pathway activation in cholangiocarcinoma, although its biological significance in initiating and promoting tumor progression remains ambiguous. This review provides an overview of the complex biochemistry behind the mTOR pathway and its role in carcinogenesis, especially as it pertains to hepatic malignancies.

UR - http://www.scopus.com/inward/record.url?scp=84881015181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881015181&partnerID=8YFLogxK

U2 - 10.1002/hep.26323

DO - 10.1002/hep.26323

M3 - Article

C2 - 23408390

AN - SCOPUS:84881015181

VL - 58

SP - 810

EP - 818

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 2

ER -